Research programme: polypeptide conjugated therapeutics - Amunix/Roche
Latest Information Update: 29 Oct 2015
At a glance
- Originator Amunix; Roche
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified